The dermatological consequences of obesity

International Journal of Dermatology

Volumn 52, Issue 8, 2013, Pages 927-932

  Tobin, Anne Marie ^a   Ahern, Tomas ^a   Rogers, Sarah ^a   Collins, Paul ^a   O'Shea, Donal ^a   Kirby, Brian ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ANDROGEN; CORTICOSTEROID; HEMOGLOBIN; INSULIN; LEPTIN; METHOTREXATE; PROOPIOMELANOCORTIN; TUMOR NECROSIS FACTOR ALPHA;

ACANTHOSIS NIGRICANS; ACNE; BODY MASS; CANCER RISK; CANDIDA FOLLICULITIS; CANDIDIASIS; CELLULITIS; CHRONIC VEIN INSUFFICIENCY; CUTANEOUS MELANOMA; DISEASE ASSOCIATION; FIBROMA; FOLLICULITIS; HIRSUTISM; HUMAN; HYPERINSULINEMIA; HYPERKERATOSIS; INTERTRIGO; LYMPHEDEMA; MALE TYPE ALOPECIA; NON MELANOMA SKIN CANCER; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; PSORIASIS; REVIEW; RISK FACTOR; SKIN DISEASE; SKIN INFECTION; STRIA; SUPPURATIVE HIDRADENITIS; ULCER; VENOUS STASIS;

HUMANS; INCIDENCE; OBESITY; PSORIASIS; RISK FACTORS; SKIN NEOPLASMS;

EID: 84880652867     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2012.05624.x     Document Type: Review

References (57)

1. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 1998; 22: 39-47.
2. Yan LL, Daviglus ML, Liu K, et al. Midlife body mass index and hospitalization and mortality in older age. JAMA 2006; 295: 190-198.
3. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295: 1549-1555.
4. Renehan AG, Tyson M, Egger M, et al. Body mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569-578.
5. Danielsson G, Eklof B, Grandinetti A, Kistner RL. The influence of obesity on chronic venous disease. Vasc Endovascular Surg 2002; 36: 271-276.
6. Burkitt DP. Varicose veins: facts and fantasy. Arch Surg 1976; 111: 327-330.
7. Sugerman HJ, Sugerman EL, Wolfe L, et al. Risks and benefits of gastric bypass in morbidly obese patients with severe venous stasis disease. Ann Surg 2001; 234: 41-46.
8. Fowkes FG, Evans CJ, Lee AJ. Prevalence and risk factors of chronic venous insufficiency. Angiology 2001; 52(Suppl.): 5-15.
9. Ragnarson Tennvall G, Hjelmgren J. Annual costs of treatment for venous leg ulcers in Sweden and the United Kingdom. Wound Repair Regen 2005; 13: 13-18.
10. Carratalà J, Rosón B, Fernández-Sabé N, et al. Factors associated with complications and mortality in adult patients hospitalized for infectious cellulitis. Eur J Clin Microbiol Infect Dis 2003; 22: 151-157.
11. O'Donnell TF Jr. The management of primary lymphedema. In: Ernst CB, Stanley CJ, eds. Current Therapy in Vascular Surgery, 2nd edn. Philadelphia, PA: BC Decker, 1991: 1022-1029.
12. Lewis SD, Peter GS, Gómez-Marín O, Bisno AL. Risk factors for recurrent lower extremity cellulitis in a US Veterans Medical Center population. Am J Med Sci 2006; 332: 304-307.
13. Thorsteindottir B, Tleyjeh IM, Baddour LM. Abdominal wall cellulitis in the morbidly obese. Scand J Infect Dis 2005; 37: 605-608.
14. Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008; 59: 596-601.
15. Slade DE, Powell BW, Mortimer PS. Hidradenitis suppurativa: pathogenesis and management. Br J Plast Surg 2003; 56: 451-461.
16. Brown TJ, Rosen T, Orengo IF. Hidradenitis suppurativa. South Med J 1998; 12: 1107-1114.
17. Harrison BJ, Read GF, Hughes LE. Endocrine basis for the clinical presentation of hidradenitis suppurativa. Br J Surg 1988; 75: 972-975.
18. Edlich RF, Silloway KA, Rodeheaver GT, Cooper PH. Epidemiology, pathology, and treatment of axillary hidradenitis suppurativa. J Emerg Med 1986; 4: 369-378.
19. Ross EV, Baxter DL Jr. Widespread candida folliculitis in a non-toxic patient. Cutis 1992; 49: 241-243.
20. Hsu HS, Chen W, Chen SC, Ko FD. Colored striae in obese children and adolescents. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 1996; 37: 349-352.
21. Arem AJ, Kischer CW. Analysis of striae. Plast Reconstr Surg 1980; 65: 22-29.
22. Light D, Arvanitis GM, Abramson D, Glasberg SB. Effect of weight loss after bariatric surgery on skin and the extracellular matrix. Plast Reconstr Surg 2010; 125: 343-351.
23. Simkin B, Arce R. Steroid excretion in obese patients with colored abdominal striae. N Engl J Med 1982; 266: 1031-1035.
24. Cordeiro RC, Zecchin KG, de Moraes AM. Expression of estrogen, androgen, and glucocorticoid receptors in recent striae distensae. Int J Dermatol 2010; 49: 30-32.
25. Demir S, Demir Y. Acrochordon and impaired carbohydrate metabolism. Acta Diabetol 2002; 39: 57-59.
26. Erdoǧan BS, Aktan S, Rota S, et al. Skin tags and atherosclerotic risk factors. J Dermatol 2005; 32: 371-375.
27. Hud JA Jr, Cohen JB, Wagner JM, Cruz PD Jr. Prevalence and significance of acanthosis nigricans in an adult obese population. Arch Dermatol 1992; 128: 941-944.
28. García-Hidalgo L, Orozco-Topete R, Gonzalez-Barranco J, et al. Dermatoses in 156 obese adults. Obes Res 1999; 7: 299-302.
29. Cruz PD Jr, Hud JA Jr. Excess insulin binding to insulin-like growth factor receptors: proposed mechanism for acanthosis nigricans. J Invest Dermatol 1992; 98(Suppl. 6): 82-85.
30. Wild RA. Obesity, lipids, cardiovascular risk, and androgen excess. Am J Med 1995; 98(Suppl.): 27-32.
31. Reingold SB, Rosenfield RL. The relationship of mild hirsutism or acne in women to androgens. Arch Dermatol 1987; 123: 209-212.
32. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73.
33. Kimball AB, Robinson D Jr, Wu Y, et al. Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002. Dermatology 2008; 217: 27-37.
34. Cohen AD, Sherf M, Vidavsky L, et al. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008; 216: 152-155.
35. Wolk K, Mallbris L, Larsson P, et al. Excessive body weight and smoking associates with a high risk of onset of plaque psoriasis. Acta Derm Venereol 2009; 89: 492-497.
36. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125: 61-67.
37. Herron MD, Hinckley M, Hoffman MS, Papenfuss J, Hansen CB, Callis KP, Krueger GG. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005; 141: 1527-1534.
38. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298: 321-328.
39. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, Giannetti A, Girolomoni G. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73.
40. Bardazzi F, Balestri R, Baldi E, et al.Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy. Dermatologic therapy 2010; 23: S14-S19.
41. Hamminga EA, van der Lely AJ, Neumann HA, Thio HB. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses 2006; 67: 768-773.
42. Higa-Sansone G, Szomstein S, Soto F, et al. Psoriasis remission after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes Surg 2004; 14: 1132-1134.
43. de Menezes Ettinger JE, Azaro E, de Souza CA, et al. Remission of psoriasis after open gastric bypass. Obes Surg 2006; 16: 94-97.
44. Gisondi P, Del Giglio M, Di Francesco V, et al. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr 2008; 88: 1242-1247.
45. Samanic C, Gridley G, Chow WH, et al. Obesity and cancer risk among white and black United States veterans. Cancer Causes Control 2004; 15: 35-43.
46. Samanic C, Chow WH, Gridley G, et al. Relation of body mass index to cancer risk in 362, 552 Swedish men. Cancer Causes Control 2006; 17: 901-909.
47. Courneya KS, Katzmarzyk PT, Bacon E. Physical activity and obesity in Canadian cancer survivors: population-based estimates from the 2005 Canadian Community Health Survey. Cancer 2008; 112: 2475-2482.
48. Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 2007; 335: 1134-1139.
49. Gallus S, Naldi L, Martin L, et al. Anthropometric measures and risk of cutaneous malignant melanoma: a case-control study from Italy. Melanoma Res 2006; 16: 83-87.
50. Dennis LK, Lowe JB, Lynch CF, Alavanja MC. Cutaneous melanoma and obesity in the Agricultural Health Study. Ann Epidemiol 2008; 18: 214-221.
51. Pelucchi C, Naldi L, Di Landro A, et al. Anthropometric measures, medical history and risk of basal cell carcinoma in an Italian case-control study. Dermatology 2008; 216: 271-276.
52. Millington GW. Proopiomelanocortin (POMC): the cutaneous roles of its melanocortin products and receptors. Clin Exp Dermatol 2006; 31: 407-412.
53. Millington GW. The role of proopiomelanocortin (POMC) neurones in feeding behavior. Nutr Metab (Lond) 2007; 4: 4-18.
54. Gogas H, Trakatelli M, Dessypris N, et al. Melanoma risk in association with serum leptin levels and lifestyle parameters: a case-control study. Ann Oncol 2008; 19: 384-389.
55. Katiyar SK, Meeran SM. Obesity increases the risk of UV radiation-induced oxidative stress and activation of MAPK and NF-kappaB signaling. Free Radic Biol Med 2007; 42: 299-310.
56. Sharma SD, Katiyar SK. Leptin deficiency-induced obesity exacerbates ultraviolet B radiation-induced cyclooxygenase-2 expression and cell survival signals in ultraviolet B-irradiated mouse skin. Toxicol Appl Pharmacol 2010; 244: 328-335.
57. Lynch LA, O'Connell JM, Kwasnik AK, et al. Are natural killer cells protecting the metabolically healthy obese patient?Obesity (Silver Spring) 2009; 17: 601-605.